Document is current
Any future updates will be listed below
-
Authors
Lee, Brian P.
Witkiewitz, Katie
Mellinger, Jessica
Anania, Frank A.
Bataller, Ramon https://orcid.org/0000-0002-1119-7799
Cotter, Thomas G.
Curtis, Brenda
Dasarathy, Srinivasan https://orcid.org/0000-0003-1774-0104
DeMartini, Kelly S.
Diamond, Ivan
Diazgranados, Nancy https://orcid.org/0000-0002-7415-8455
DiMartini, Andrea F.
Falk, Daniel E.
Fernandez, Anne C.
German, Margarita N. https://orcid.org/0000-0003-3337-6760
Kamath, Patrick S. https://orcid.org/0000-0002-7888-1165
Kidwell, Kelley M.
Leggio, Lorenzo
Litten, Raye
Louvet, Alexandre
Lucey, Michael R.
McCaul, Mary E.
Sanyal, Arun J.
Singal, Ashwani K. https://orcid.org/0000-0003-1207-3998
Sussman, Norman L.
Terrault, Norah A.
Thursz, Mark R.
Verna, Elizabeth C.
Radaeva, Svetlana
Nagy, Laura E. https://orcid.org/0000-0002-0580-2809
Mitchell, Mack C. https://orcid.org/0000-0001-9018-7988
- License Information
-
More Information
Article History
Accepted: 22 April 2024
First Online: 7 June 2024
Competing interests
: R.B. is a consultant for GlaxoSmithKline and Novo Nordisk. B.P.L. is a consultant for GlaxoSmithKline, Novo Nordisk and HepaTX. J.M. is a consultant for GlaxoSmithKline. I.D. is on the Board of Amygdala Neuroscience. A.J.S. has ownership interests in Durect, Tiziana, Exhalenz, Inversago, Galmed and Genfit and is a consultant to Intercept, Gilead, Merck, Boehringer Ingelhiem, Eli Lilly, Novo Nordisk, 89BIO, Pfizer, Regeneron, Avant Sante, Hemoshear, Takeda, GlaxoSmithKline, Amgen, Genentech, Histoindex, Path AI, Bristol Myers Squibb, Malinckrodt, Salix, Ocelot, Astra Zeneca, Madrigal, Hanmi, LG and Fortress Bio. A.L. is a consultant for GlaxoSmithKline. M.R.T. is a consultant for GlaxoSmithKline, Resolution Therapeutics, HepaTx, Galecto, Durect, Intercept and Prodigy. M.R.L. receives research support from TARGET PharmaSolutions, AbbVie to University of Wisconsin. E.C.V. receives research support from Salix. N.A.T. receives research support from GSK; Genentech-Roche; Helio Health; Durect Corp; Gilead Sciences; Eiger Pharmaceuticals; Madrigal to her institution. N.L.S. is an employee of Durect Corporation. K.W. is a member of the Alcohol Clinical Trials Initiative (ACTIVE) Workgroup. In the past 36 months, its activities were supported by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi and Otsuka. M.C.M. is a consultant for GlaxoSmithKline, Prodigy, HepaTX and a Board member of Amygdala Neuroscience; research support to his institution from Durect. The other authors declare no competing interests.
Free to read: This content has been made available to all.
